The interleukin-2 receptor: a target for immunotherapy.
Waldmann
T A
TA
Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
Goldman
C
C
Top
L
L
Grant
A
A
Burton
J
J
Bamford
R
R
Roessler
E
E
Horak
I
I
Zaknoen
S
S
Kasten-Sportes
C
C
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015490:HTLV-I Infections / Q000276:immunology / Q000628:therapy; D006801:Humans; D007167:Immunotherapy; D000922:Immunotoxins / Q000627:therapeutic use; D015458:Leukemia, T-Cell / Q000276:immunology / Q000628:therapy; D009369:Neoplasms / Q000276:immunology; D015375:Receptors, Interleukin-2 / Q000032:analysis / Q000737:chemistry / Q000276:immunology / Q000502:physiology*
D000911:Antibodies, Monoclonal; D000922:Immunotoxins; D015375:Receptors, Interleukin-2